1.. INTRODUCTION
================

1.1.. Schizophrenia
-------------------

Schizophrenia is a chronic neuropsychiatric illness affecting approximately 1% of the global population \[[@R1], [@R2]\]. Individuals with the disorder may experience hallucinations, delusions, suspiciousness, and conceptual disorganization among other so called positive symptoms. These positive symptoms can be accompanied by social withdrawal, blunted affect, emotional withdrawal and asociality, collectively referred as negative symptoms. Cognitive impairment is also a core feature of schizophrenia \[[@R3]\]. Together with other residual symptoms including depression, the broad array of symptoms associated with schizophrenia results in significant impairment of social function with the inability to fully integrate into one's family and into the workplace. Although the etiology and pathology of schizophrenia remain largely un-resolved \[[@R4]-[@R6]\], dopamine system dysfunction clearly contributes to the pathophysiology of this disorder \[[@R7]-[@R9]\]. Subsequent research suggests that the serotonergic pathway also plays an important role \[[@R10]\]. Recent molecular genetic studies conducted by an international schizophrenia consortium strongly support the fact that schizophrenia is a polygenic disease \[[@R11]\].

1.2.. Current Treatments for Schizophrenia
------------------------------------------

It is well accepted that the positive symptoms of schizophrenia are associated with hyperdopaminergic neurotransmission in the brain, particularly in the mesolimbic dopamine pathway, while the negative symptoms and cognitive deficits associated with schizophrenia may be caused by hypodopaminergic activity in the mesocortical pathway \[[@R12]-[@R16]\]. Dopamine D~2~ receptor antagonists, such as chlorpromazine and haloperidol, have demonstrated clinical efficacy in the reduction of positive symptoms. However, these first generation antipsychotics are ineffective and may exacerbate negative symptoms and cognitive deficits associated with schizophrenia. As detailed below, they bind to a number of receptor systems, many of which contribute to serious side effects. Although modulating dopamine neurotransmission

has been a dominant therapeutic approach, findings from both clinical and preclinical research have suggested that dysregulation of other neurotransmitter systems including serotonin, glutamate, gamma-aminobutyric acid (GABA) and acetylcholine also contribute to the pathophysiology of schizophrenia \[[@R17]\]. The dysfunction of multiple neurotransmitter systems in schizophrenia indicated that drugs selectively targeting one neurotransmission pathway are unlikely to meet the therapeutic needs of this heterogeneous disorder. Treatment involving the modulation of multiple targets may be more effective to address social dysfunction as well as positive symptoms associated with schizophrenia. In this article, we will review marketed typical and atypical antipsychotics as well as novel therapeutic agents targeting dopamine D~2~ receptors and other neurotransmitters systems for the treatment of schizophrenia. The structure-activity relationships (SAR) and receptor binding profiles of these compounds will be discussed. Representative compounds from each generation of antipsychotics will be compared in various aspects including pharmacological profiles, efficacy in behavioral models, clinical outcomes and associated side effects.

2.. DEVELOPMENT OF ANTIPSYCHOTICS FOR THE TREATMENT OF SCHIZOPHRENIA
====================================================================

Since the first antipsychotic, chlorpromazine (**1**), was introduced in the 1950s \[[@R18]\], many other antipsychotic drugs have been discovered and marketed during the past six decades. While the chemical structures of these antipsychotics are quite diverse, they all have somewhat similar pharmacological action, mainly dopamine D2 receptor blockade. These compounds generally can be classified as "typical" and "atypical" antipsychotics based upon both pattern of clinical effects and mechanism of action \[[@R19], [@R20]\]. The typical antipsychotic drugs, represented by haloperidol (**2**) and chlorpromazine (**1**), are also called the first generation antipsychotics (FGA) or neuroleptics. The FGAs are effective at reducing positive symptoms associated with schizophrenia, but are largely limited by extrapyramidal motor side effects (EPS), hyperprolactinemia and cognitive dulling. These adverse effects are likely mediated by high dopamine D~2~ receptor occupancy. The serendipitous discovery of compounds such as clozapine (**3**) defined a new generation of antipsychotic medications, referred to as the atypical antipsychotics. The atypical antipsychotics, including clozapine (**3**) and risperidone (**4**), are considered as the second generation antipsychotics (SGA). Serotonin 5-HT~2A~ receptor antagonism in combination with D~2~ receptor antagonism is thought to be the hallmark pharmacology of the SGAs. The SGAs have reduced EPS liability compared to the FGAs, but can be associated with increased weight gain and metabolic burden mediated by unintended off-target pharmacological interactions \[[@R21]\]. Many are still associated with high rates of akathisia even though rates of parkinsonism have been reduced in some compounds. Clozapine, arguably the most effective antipsychotic, has a myriad of safety issues that precludes it from being used as a first-line therapy. The more recently marketed antipsychotics with D~2~ receptor partial agonist effects rather than D~2~ antagonism, as exemplified by aripiprazole (**5**) and brexpiprazole (**6**), are still considered as atypical antipsychotics, though these drugs were marketed as the third generation antipsychotics. Presynaptic partial agonism at D~2~ receptors has allowed for a further reduction in EPS and hyperprolactinemia, but postsynaptic partial agonism at D~2~ receptors has been associated with relatively high levels of akathisia and more recently with uncontrollable pathological urges to gamble, binge eat, shop and have sex \[[@R22]\]. Currently, new investigational drugs with novel mechanisms are being developed in order to identify better therapeutic agents that can treat not only the positive symptoms of schizophrenia but also enhance social function and improve safety and tolerability. For instance, ITI-007 (**7**) represents a first-in-class small molecule therapeutic agent interacting with serotonergic, dopaminergic and glutamatergic neurotransmitter targets in a complex, unique and regionally selective manner \[[@R23], [@R24]\]. We will briefly review the first and second generation antipsychotics since these antipsychotics have been reviewed extensively \[[@R25]-[@R27]\]. Newer antipsychotic drug candidates targeting dopamine along with other neurotransmitter systems will be discussed in detail. Representative antipsychotic drugs, haloperidol (**2**), clozapine (**3**), risperidone (**4**), aripiprazole (**5**), and ITI-007 (**7**), representing a new investigational drug for schizophrenia, will be systematically reviewed.

2.1.. Haloperidol and Other First-Generation Antipsychotics (FGA)
-----------------------------------------------------------------

Typical antipsychotics exert their action predominantly through dopamine D~2~ receptor antagonism. As exemplified in (Fig. **[1](#F1){ref-type="fig"}**), these first generation antipsychotics may be generally categorized into several chemical classes, including (a) phenothiazines, such as chlorpromazine (**1**) \[[@R28], [@R29]\], perphenazine (**8**) \[[@R30], [@R31]\], fluphenazine (**9**) \[[@R32], [@R33]\], trifluoperazine (**10**) \[[@R34], [@R35]\] and levomepromazine (**11**) \[[@R36]\], (b) thioxanthenes, such as chlorprothixene (**12**) \[[@R37], [@R38]\], clopenthixol (**13**) \[[@R39]\] and thiothixene (**14**) \[[@R40]\], and (c) diphenylbutylpiperidines, such as pimozide (**15**) \[[@R41], [@R42]\], fluspirilene (**16**) \[[@R43]\] and penfluridol (**17**) \[[@R44]\].

Butyrophenones are another important class of compounds with antipsychotic activities. Haloperidol (**2**) is a well-known typical antipsychotic drug that belongs to this chemical class \[[@R45], [@R46]\]. Other drugs, such as bromperidol (**18**) \[[@R47], [@R48]\], trifluperidol (**19**) \[[@R49]\], lenperone (**20**) \[[@R50]\], benperidol (**21**) \[[@R51], [@R52]\], droperidol (**22**) \[[@R53]\], pipamperone (**23**) \[[@R54], [@R55]\] and spiperone (**24**) \[[@R56]\] are also from this family (Fig. **[2](#F2){ref-type="fig"}** ). As summarized in Table **[1](#T1){ref-type="table"}**, these butyrophenones have different receptor binding profiles. Each of these compounds exhibited different clinical efficacy. For instance, bromperidol (**18**) possesses a dopamine D~2~ receptor binding affinity similar to that of haloperidol, yet it has an apparent elimination half-life of approximately 24 h, supporting a once-daily dose regimen \[[@R57]\]. Trifluperidol (**19**) is a more potent neuroleptic drug than haloperidol and has been studied in withdrawn and autistic patients with schizophrenia. Benperidol (**21**) and spiperone (**24**) are two of the most potent antipsychotic drugs in the butyrophenone family, though not approved for use in the United States. Spiperone has shown efficacy in treating drug-resistant schizophrenia \[[@R58]\]. Droperidol is a short-acting neuroleptic drug with pronounced antiemetic and anti-shock properties \[[@R59]\], though it is not used for the treatment of schizophrenia due to its short duration of action. Pipamperone is generally classified as a

first-generation typical antipsychotic, yet it possessed prominent serotonin 5-HT~2A~ binding affinity (Table **[1](#T1){ref-type="table"}**), and was considered as a forerunner of atypical antipsychotics \[[@R60]\].

Among these typical antipsychotics, haloperidol (**2**) is the most commonly used, so its properties will be extensively reviewed in this article and compared with representative examples of newer generations of antipsychotics. Haloperidol was first synthesized by Bert Hermans at the Janssen Laboratories in Belgium in February, 1958. It was given the generic name of haloperidol because of the two halogenated substituents incorporated into the molecule \[[@R62]\]. Under the brand name Haldol^®^, haloperidol was marketed in Belgium in 1959, and later marketed in United States and other countries. It is currently on the World Health Organization (WHO) Model List of Essential Medicines \[[@R63]\]. This compound preferentially binds to dopamine and α~1~-adrenergic receptors with negligible affinity for serotonin 5-HT~2C~, histamine H~1~ and muscarinic M~1~ receptors (Table **1**), which are thought to be associated with adverse effects of marketed antipsychotics \[[@R64]-[@R66]\].

Haloperidol is extensively metabolized in the liver. In human, the compound primarily undergoes glucuronidation \[[@R67]\], ketone reduction to stereoselectively generate the (*S*)-enantiomer of reduced haloperidol (**25**) via a ketone reductase \[[@R68]\], and *N-*dealkylation to give dealkylated metabolites (**26 -- 28**) via cytochrome P450 3A4 and 2D6 \[[@R69], [@R70]\]. The reduced haloperidol (**25**) can also be back converted to haloperidol via CYP 3A4, as shown in [Fig. (**[3](#F3){ref-type="fig"}**)](#F3){ref-type="fig"} \[[@R71], [@R72]\]. It has been suggested that haloperidol (**2**) is also subjected to cytochrome P450 mediated metabolism to form pyridinium metabolites (**29** and **30**), structural analogues of MPP^+^ (1-methyl-4-phenylpyridinium) \[[@R73]-[@R75]\]. In psychiatric patients treated with haloperidol chronically, the severity of tardive dyskinesia and parkinsonism appears to be associated with an increased ratio of pyridinium (**28**) to haloperidol \[[@R76]\]. To prevent the formation of pyridinium metabolites, new chemical series of antipsychotic agents designed based upon

the haloperidol scaffold have been reported in recent years \[[@R77], [@R78]\].

2.2.. Clozapine, Risperidone, Aripiprazole and other Second-Generation Antipsychotics (SGA)
-------------------------------------------------------------------------------------------

Unlike the typical antipsychotics, which preferentially block dopamine D~2~ receptors, the second-generation antipsychotic drugs not only reduce dopamine neurotransmission, but also act on serotonin receptors, especially 5-HT~2A~ receptors and typically as antagonists \[[@R79]\]. Biochemical, electrophysiological and behavioral studies have shown that 5-HT~2A~ receptor antagonists have antipsychotic-like activity \[[@R80]\]. The highly selective 5-HT~2A~ antagonist, MDL-100907 (**31**) exhibited antipsychotic activity in several preclinical animal models \[[@R81], [@R82]\], but it failed, like other selective 5-HT~2A~ antagonists, to exhibit sufficient efficacy in clinical trials to be approved for the treatment of schizophrenia \[[@R83]\]. To achieve better efficacy, blockade of both serotonin 5-HT~2A~ and dopamine D~2~ receptors is warranted at clinically effective doses. There is now considerable preclinical and some clinical evidence that effects on 5-HT receptors contribute to the low risk of producing EPS, which is the defining characteristic of the atypical antipsychotics, compared to typical antipsychotics \[[@R84], [@R85]\].

Importantly, the data suggest that 5-HT~2A~ receptor antagonism potentiates mesolimbic D~2~ receptor antagonist-mediated efficacy, but does not alter nigrostriatal D~2~ receptor antagonist-mediated motor side effects. Ritanserin, a 5-HT~2A/C~ receptor antagonist, enhanced raclopride-induced dopamine concentrations in the medial prefrontal cortex and raclopride-induced increases in accumbal dopamine signal, but not in the striatum \[[@R86]\]. Ritanserin potentiated raclopride's antipsychotic-like efficacy without increasing raclopride-induced catalepsy \[[@R87]\]. Similarly, pimavanserin (ACP-103), a 5-HT~2A~ receptor inverse agonist, potentiated haloperidol's antipsychotic-like efficacy in animal models, but did not increase haloperidol-induced catalepsy \[[@R88]\]. Pimavanserin was also shown to significantly decrease haloperidol- or risperidone-induced hyperprolactinemia in animal models \[[@R88]\]. As adjunctive to antipsychotics in patients with schizophrenia, pimavanserin enhanced the efficacy of a low subtherapeutic dose of risperidone without increasing motor side effects, but did not enhance the efficacy of a low therapeutic dose of haloperidol \[[@R89]\]. Pimavanserin is not approved for use in schizophrenia. To date, no selective 5-HT~2A~ receptor antagonists or inverse agonists have shown convincing antipsychotic efficacy as a monotherapy for the treatment of schizophrenia, but the pharmacological mechanism of blocking 5-HT~2A~ receptors is thought to play an important role, together with D~2~ receptor blockade, in the efficacy of atypical antipsychotics.

The serendipitous discovery of clozapine (**3**) in the 1960s opened the second major chapter in the pharmacological treatment of schizophrenia. Clozapine exerted antipsychotic effects in humans with a markedly reduced risk of EPS or hyperprolactinemia at efficacious doses. This profile was sufficiently different from the first generation of antipsychotics that clozapine became the prototype of the so-called atypical antipsychotic drugs. A number of second-generation antipsychotics were developed based upon clozapine, such as risperidone (**4**), olanzapine (**32**), quetiapine (**33**), paliperidone (**34**), ziprasidone (**35**), sertindole (**36**), iloperidone (**37**) and lurasidone (**38**), as shown in [Fig. (**[4](#F4){ref-type="fig"}**)](#F4){ref-type="fig"}. These atypical antipsychotics have somewhat different pharmacological profiles, yet they all have antagonistic activity on dopaminergic D~2~ and serotoninergic 5-HT~2A~ receptors. These atypical antipsychotics can be divided mechanistically into those that bind to multiple other neuroreceptors including modest affinity to D~2~ and 5-HT~2A~, such as clozapine, olanzapine and quetiapine, and those that exhibit potent D~2~ and 5-HT~2A~ antagonistic activities, such as risperidone, paliperidone, sertindole and lurasidone, as summarized in Table **[2](#T2){ref-type="table"}**. Among these SGA, clozapine (**3**) and risperidone (**4**) are the most widely used, and so these two antipsychotics were selected for extensive review and comparison with other generations of antipsychotic drugs.

Clozapine (**3**) has a very rich pharmacology, targeting a wide range of receptors including adrenergic, muscarinic, histaminergic, dopaminergic and serotonergic receptors. Clozapine was developed by Sandoz in 1961 and first introduced in Europe in the 1970s. It was later withdrawn from the market after reports of clozapine-induced agranulocytosis that led to death in some patients \[[@R90]\]. Clozapine is known to cause weight gain and metabolic disturbances and is also associated with an increased incidence of seizures and myocarditis \[[@R91]\]. Despite the tremendous safety burden, clozapine is arguably the most efficacious antipsychotic drug and was reintroduced into the US market in 1990, and used only for treatment-resistant schizophrenia \[[@R92], [@R93]\]. Clozapine is eliminated by oxidation in the liver, predominantly by CYP1A2 \[[@R94], [@R95]\]. Smoking, a potent inducer of CYP1A2 enzyme activity, results in significantly lower clozapine serum concentrations in smokers compared with non-smokers \[[@R96]\]. *N*-Desmethylclozapine (norclozapine) and clozapine *N-*oxide are major metabolites of clozapine \[[@R97]\]. Studies have indicated that clozapine may be transformed by bioactivation to a chemically reactive nitrenium ion, which may play an important role in the pathogenesis of clozapine-induced agranulocytosis \[[@R98], [@R99]\]. Olanzapine (**32**) and clozapine (**3**) have very similar structures, and olanzapine was also found to be oxidized to a reactive nitrenium intermediate by hypochlorous acid (HOCl), which is a major oxidant produced by activated neutrophils. However, the incidence of agranulocytosis caused by olanzapine is much lower than that of clozapine \[[@R100]\]. Through the substitution of sulfur for the bridging nitrogen in the dibenzodiazepine-type antipsychotic clozapine, the dibenzothiazepine-type compound quetiapine (**33**) does not directly form a nitrenium ion when incubated with myeloperoxidase. However, quetiapine was found to be metabolized to 7-hydroxyquetiapine, which can subsequently be oxidized by human myeloperoxidase to form a reactive quinone-imine and a reactive radical. This drug metabolism was reported to lead to continued, although reduced, neutrophil toxicity \[[@R101]\].

Risperidone (**4**) represents another group of atypical antipsychotics. It has potent dopaminergic D~2~ and serotonergic 5-HT~2A~ antagonistic activities with high affinity to adrenergic and histaminergic receptors. Risperidone was developed by Janssen-Cilag between 1988 and 1992 and was first approved by the FDA in 1993 for the treatment of schizophrenia in adults. Later, it was approved for the short-term treatment of acute manic or mixed episodes associated with bipolar disorder and the treatment of irritability associated with autistic disorder. It is currently on the WHO Model List of Essential Medicines, along with chlorpromazine (**1**), haloperidol (**2**), clozapine (**3**) and fluphenazine (**9**), for the treatment of mental and behavioral disorders \[[@R63]\]. The treatment-related adverse effects of risperidone, such as weight gain, orthostatic hypotension and sedation, are reported to be caused by the high binding affinity of the compound to 5-HT~2C~, adrenergic α~1~ and histaminergic H~1~ receptors, which will be discussed and compared with other antipsychotics in another section. Risperidone in humans is metabolized to 9-hydroxy risperidone (paliperidone (**34**)) by CYP2D6 and, to a lesser extent, CYP3A4 \[[@R104]\].

Aripiprazole (**5**) is a relatively new antipsychotic drug representing the third group of atypical antipsychotics \[[@R105], [@R106]\]. Unlike clozapine (**3**) and risperidone (**4**), which are pure antagonists of dopaminergic and serotonergic receptors, aripiprazole acts as a partial agonist at the serotonin 5-HT~1A~ receptors and the pre- and postsynaptic dopamine D~2~ receptors, and as an antagonist at the serotonin 5-HT~2A~ receptors \[[@R107]-[@R109]\]. It was marketed as the prototype of the third-generation of antipsychotics, the so-called dopamine system stabilizers \[[@R26], [@R110], [@R111]\]. Aripiprazole is primarily metabolized by CYP3A4 and CYP2D6, forming mainly an active metabolite, dehydroaripiprazole (**39**) \[[@R112]\]. The concentration of this active metabolite typically accumulated to about 40% of the parent compound concentration \[[@R113]\]. Brexpiprazole (**6**) may be considered as an analog of the dehydration metabolite of aripiprazole. The dichlorophenyl group substituted on the piperazinyl ring in dehydroaripiprazole (**39**) was replaced with a benzothiophenyl group in brexpiprazole (**6**), as shown in [Fig (**5**)](#F5){ref-type="fig"}. Brexpiprazole functions a partial agonist at pre- and post synaptic dopamine D~2~ and D~3~ receptors and is more potent at serotonin 5-HT~1A~ (partial agonist) and 5-HT~2A~ (antagonist) and adrenergic α~1B~ (antagonist) receptors in comparison with aripiprazole (Table **[3](#T3){ref-type="table"}**) \[[@R114], [@R115]\]. On July 10, 2015, brexpiprazole (Rexulti) was approved by FDA to treat adults with schizophrenia and as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder (MDD) \[[@R116]\]. Cariprazine (**40**) is another pre- and post synaptic dopamine D~2~ and D~3~ partial agonist that was recently approved by FDA for the treatment of schizophrenia and bipolar disorder in adults \[[@R117]\]. It has a higher affinity for dopamine D~3~ receptors versus D~2~ receptors, and exhibited low affinity at human serotonin 5-HT~2A~ receptors \[[@R118]\]. All three of these atypical antipsychotics contain characteristic (4-arylpiperazin-1-yl)alkyl groups. The differences and similarities of these drugs as dopamine receptor partial agonists have been systematically reviewed \[[@R119]\]. In this article, we will focus on the comparisons of aripiprazole (**5**), a representative antipsychotic drug from this class, with other classes of typical and atypical antipsychotics.

2.3.. ITI-007 and Other Investigational New Drugs Targeting Dopamine
--------------------------------------------------------------------

In addition to the approved antipsychotic drugs described above, a few new drug candidates targeting dopamine and other neuroreceptors, such as ITI-007 (**7**), bifeprunox (**41**), zicronapine (**42**), Lu AF35700 (**43**) and RP5063 (**44**), entered late stage clinical development for schizophrenia and other neuropsychiatric disorders.

ITI-007 (**7**) represents a new approach to the treatment of schizophrenia, targeting an improvement in social function in addition to antipsychotic efficacy and an associated highly favorable safety and tolerability profile. ITI-007 is a small molecule therapeutic agent interacting with serotonergic, dopaminergic and glutamatergic neurotransmitter targets in a complex, unique and regionally selective manner \[[@R23], [@R24]\]. ITI-007 is designed specifically to combine potent serotonin 5-HT~2A~ receptor antagonism with modulation of phosphoprotein pathways downstream of dopamine receptors and with serotonin reuptake inhibition. ITI-007 has dual properties, acting as a post-synaptic antagonist and as a pre-synaptic partial agonist at dopamine D~2~ receptors *in vivo* with mesolimbic/mesocortical selectivity \[[@R23]\]. Though the effect of ITI-007 at pre-synaptic D~2~ receptors resembles that of aripiprazole \[[@R106], [@R107]\], the post-synaptic D~2~ interactions are different. Whereas aripiprazole is a partial agonist at pre-synaptic and post-synaptic receptors, ITI-007 is an antagonist at post-synaptic receptors. The structural features of the compound responsible for this unique interaction at D~2~ receptors for ITI-007 have not been defined. ITI-007 also indirectly modulates glutamatergic activity by increasing the phosphorylation of the NR2B (or GluN2B) subunit of N-methyl-D-aspartate (NMDA) channels in extrastriatal dopamine-rich brain regions (e.g. nucleus accumbens). The precise molecular pathway underlying this effect of ITI-007 has not been elucidated, though phosphorylation of NR2B at the tyrosine-1472 (Y1472) residue is known to be regulated through a pathway downstream of dopamine D~1~ receptor activation impacting Fyn kinase \[[@R123]\]. The spectrum of biochemical actions is referred to as dopamine receptor protein phosphorylation modulation (DPPM). The combination of ITI-007\'s high potency blockade of 5-HT~2A~ receptors, efficient dopamine modulation, serotonin reuptake inhibition, and indirect enhancement of glutamatergic neurotransmission has been shown to yield antipsychotic efficacy without motor side effects or cardiometabolic safety issues. ITI-007 demonstrated a reduction of positive symptoms in patients with schizophrenia comparable to risperidone, but with significantly lower blood levels of biomarkers indicative of potential metabolic dysfunction (i.e., insulin, glucose, cholesterol and triglycerides) and prolactin \[[@R124]\]. ITI-007 was also associated with lower rates of motor side effects, such as akathisia, and cardiovascular side effects, such as tachycardia, than risperidone. Moreover, ITI-007 showed a greater efficacy in the improvement of negative symptoms and prosocial behavior than risperidone. The efficacy of ITI-007 for the reduction in psychosis and improvement in social function in patients with schizophrenia was confirmed in a phase III clinical trial \[[@R125]\].

Bifeprunox (**41**) is partial agonist of dopamine D~2~ and serotonin 5-HT~1A~ receptors \[[@R126]\]. Activation of serotonin 5-HT~1A~ receptors has been shown to reduce extrapyramidal symptoms in rodent models \[[@R127], [@R128]\]. Based upon data in rats, the balance of activity at 5-HT~1A~ and D~2~ receptors may bring potential benefit to some of the negative symptoms of schizophrenia \[[@R129]\]. In a randomized, double-blind, placebo-controlled clinical study, 20 mg of bifeprunox demonstrated efficacy and produced a reduction in the positive and negative syndrome scale (PANSS) total score that was significantly different from placebo in patients with an acute exacerbation of schizophrenia \[[@R130]\]. However, this compound showed inadequate efficacy in the subsequent multinational phase III clinical trials \[[@R131]\], and so the development of bifeprunox has been terminated \[[@R132]\].

Zicronapine (**42**, Lu 31-130) exhibited potent antagonistic activities at dopamine D~1~, D~2~ and serotonin 5-HT~2A~ receptors \[[@R133]\], and showed efficacy in patients with schizophrenia in phase II clinical studies \[[@R134], [@R135]\]. In 2014, Lundbeck removed zicronapine from its development portfolio due to the development of Lu AF35700 (**43**), which was claimed to have a better drug-like profile than zicronapine \[[@R136]\]. Lu AF35700 has a novel pharmacological profile with predominant D~1~ vs. D~2~ dopamine receptor occupancy combined with high 5-HT~6~ receptor occupancy \[[@R137]\]. A phase III clinical trial has been initiated using Lu AF35700 to treat patients with treatment resistant schizophrenia \[[@R138]\].

RP5063 (**44**) is a novel dopamine-serotonin system stabilizer exhibiting potent partial agonist activity at the dopamine D~2~, D~3~, D~4~, serotonin 5-HT~1A~ and 5-HT~2A~ receptors, and antagonist activity at the serotonin 5-HT~6~ and 5-HT~7~ receptors \[[@R139]\]. RP5063 showed efficacy in patients with acute schizophrenia in a placebo controlled phase II clinical study \[[@R140]\] . Currently, the phase III trials of this investigational drug for the treatment of schizophrenia are in preparation \[[@R141]\].

Among the few investigational drug candidates targeting dopamine and other neuroreceptors, ITI-007 (**7**) represents a new approach to the treatment of schizophrenia and demonstrated positive top-line results in a recent phase III clinical trial in patients with schizophrenia \[[@R125]\]. Therefore, ITI-007 was selected as a representative new drug candidate to compare with the first- and second-generation antipsychotics, haloperidol (**2**), clozapine (**3**), risperidone (**4**) and aripiprazole (**5**).

3.. COMPARISON OF REPRESENTATIVE ANTIPSYCHOTICS, HALOPERIDOL, CLOZAPINE, RISPERIDONE, ARIPIPRAZOLE AND ITI-007
==============================================================================================================

In this section, haloperidol (**2**) from the first generation of antipsychotics, clozapine (**3**), risperidone **(4**) and aripiprazole (**5**) from the second-generation atypical antipsychotics, and the investigational new drug ITI-007 (**7**) representing a new approach for the treatment of schizophrenia were compared side-by-side in terms of receptor binding profile, mechanism of action, behavioral results in animal models, clinical outcomes, dopamine D~2~ receptor occupancy, treatment related side effects and other aspects.

3.1.. Comparison of Receptor Binding Profiles and Functional Selectivity
------------------------------------------------------------------------

Early, or first-generation treatments for schizophrenia, including haloperidol (**2**), are characterized by high affinity (i.e., nanomolar) binding to dopamine D~2~ receptors \[[@R157]\]. Haloperidol functions as a potent antagonist of D~2~ receptor-mediated inhibition of adenylyl cyclase and cellular accumulation of the second messenger molecule, cAMP \[[@R158], [@R159]\]. Second-generation antipsychotic medications, such as clozapine (**3**) and risperidone (**4**), also display high affinity binding to dopamine D~2~ receptors (Table **[4](#T4){ref-type="table"}**). Antagonism of

D~2~ receptor activity is recognized as an effective treatment for reducing positive symptoms (i.e., hallucinations and delusions) of psychosis in schizophrenic patients. Unfortunately, this activity also limits the utility of agents, such as haloperidol, due to the propensity to induce motor abnormalities including acute Parkinson-like movement deficits and dystonia, referred to generally as extrapyramidal motor syndromes, and chronic tardive dyskinesia mediated through blockade of dopamine D~2~ receptors in motor pathways of the basal ganglia \[[@R160]\]. Further, such drugs are relatively ineffective in alleviating the negative symptoms associated with schizophrenia, including asociality and depression, and also induce other troubling side effects including an elevation of serum prolactin levels \[[@R161]\].

As a class, second-generation antipsychotics (SGA) suffer from a variety of debilitating side effects, including excessive weight gain (i.e., as much as 50 pounds/year), type II diabetes, cognitive impairment, sedation, blurred vision, orthostatic hypotension, constipation, dizziness, and loss of bladder control. The side effects appear to be associated with non-selective interactions of these medications with receptors that are unrelated to antipsychotic efficacy, including serotonergic 5-HT~2C~, histaminergic H~1~, alpha-adrenergic and muscarinic receptors \[[@R162]-[@R165]\]. For example, clozapine (**3**) has a high affinity for the H~1~ histamine receptor (Table **4**), and meta-analyses show a strong correlation between risk of weight gain and H~1~ receptor affinity \[[@R65]\]. In fact, risperidone (**4**) and clozapine (**3**), which induce significant weight gain in patients, display high affinity binding to two receptors implicated in excessive weight gain, namely the H~1~ histamine receptor \[[@R162], [@R166]\], and the 5-HT~2C~ serotonin receptor \[[@R164]\]. The moderate binding affinity of aripiprazole (**5**) for the human H~1~ histamine receptor (K~i~ = 61 nM) is consistent with aripiprazole exhibiting a minimal short-term weight gain \[[@R162]\]. Aripiprazole acts as a partial agonist at the 5-HT~2C~ receptor. In the presence of antidepressants with high serotonergic activity, aripiprazole has been reported to act as an antagonist at the 5-HT~2C~ receptor, resulting in significant weight gain \[[@R167]\].

ITI-007, currently in Phase III human clinical studies, displays a receptor binding profile that predicts minimal risk for many of side effects associated with antipsychotic drugs. ITI-007 has negligible binding affinity as an antagonist at M~1~ muscarinic receptors implicated in the cognitive dulling effects common in antipsychotic drugs \[[@R163]\]. In addition, ITI-007 possesses minimal binding affinity for 5-HT~2C~ serotonin receptors (K~i~ = 173 nM) and the H~1~ histamine receptors (K~i~ \> 1000 nM) \[[@R23]\] implicated in both weight gain and the aberrant metabolic side effects leading to type II diabetes in patients treated with antipsychotic drugs \[[@R162], [@R164], [@R165]\]. Results of human clinical trials of ITI-007, to date \[[@R124], [@R125]\] have not shown significant weight gain in patients with schizophrenia, suggesting that the compound's unique receptor binding profile is key in alleviating this side effect.

3.2.. Comparison of *In Vivo* Efficacy in Preclinical Animal Models
-------------------------------------------------------------------

In the absence of an animal model that effectively encapsulates the symptoms of schizophrenia, screening of new antipsychotic medications continues to focus on models that detect activity of a particular neurotransmitter receptor subtype. The various animal models traditionally employed have been reviewed in depth by Arnt and Skarsfeldt \[[@R146]\]. Here, we briefly compare the activity of representative agents, including haloperidol (**2**), clozapine (**3**), risperidone (**4**), aripiprazole (**5**) and ITI-007 (**7**), in two assays that utilize motor readouts, namely hyperlocomotion and catalepsy. Both of these assays report on the activities at brain dopamine D~2~ receptors, but in a regionally-selective manner. They offer insight into the relative effects of compounds on efficacy compared with motor side effects. Amphetamine (AMPH)-stimulated hyperlocomotion has been demonstrated to preferentially involve activation of dopamine D~2~ receptors located in limbic dopamine pathways (e.g., nucleus accumbens) \[[@R168], [@R169]\], whereas drug-induced catalepsy involves blockade of dopamine D~2~ receptors in the striatum \[[@R146]\]. Thus, the comparative potency of compounds in hyperlocomotion and catalepsy assays provides a valuable measure of their therapeutic windows for successful control of schizophrenia symptoms without adverse motor side effects.

Of the five representative compounds, haloperidol (**2**) displays the greatest potency (i.e., sub-nanomolar ED~50~) for blockade of amphetamine-induced hyperlocomotion (Table **4**) and for induction of catalepsy \[[@R146]\]. This observation is correlated with haloperidol's potent binding affinity for and functional antagonism of dopamine D~2~ receptors (Ki = 2 nM). Notably, the ratio of the effective dose for induction of catalepsy and that for blockade of hyperlocomotion is \~1.0 \[[@R146], [@R147]\], supporting a high liability of haloperidol for extrapyramidal motor side effects at dose levels required for antipsychotic activity. Risperidone (**4**), which possesses similar high affinity binding and functional antagonism of dopamine D~2~ receptors (Ki = 4.9 nM) is less potent (\~10-fold) in inhibiting amphetamine hyperlocomotion and less effective in causing catalepsy with a ratio of effective doses for catalepsy compared to hyperlocomotion blockade of \~5.0 \[[@R146]\]. Like risperidone, both clozapine (**3**) and aripiprazole (**5**) display less potent blockade of AMPH-induced hyperlocomotion than haloperidol (Table **4**). They also display a lower propensity to induce catalepsy than either haloperidol or risperidone. The ratio of effective doses for induction of catalepsy compared to blockade of hyperlocomotion is \~10 for clozapine \[[@R146]\] and 12 for aripiprazole \[[@R146], [@R148]\]. The improved motor side effect profile of these compounds may owe, in part, to the presumed effects of all three compounds (risperidone, clozapine, and aripiprazole) on cortical serotonin 5-HT~2A~ receptors. Significantly, clozapine and other newer molecules, in particular, aripiprazole, are also believed to demonstrate preferential effects on dopamine D~2~ receptors in limbic dopamine pathways, compared with catalepsy-producing receptors in the nigrostriatal pathways \[[@R170]-[@R172]\]. Further, aripiprazole has been shown to exhibit partial agonist activity at pre- and postsynaptic dopamine D~2~ receptors in the nigrostriatal system, further reducing the expression of motor side effects \[[@R172]\].

ITI-007 (**7**) demonstrates a preclinical profile that includes potent blockade of AMPH-induced hyperlocomotion (Table **4**) consistent with its high-affinity for D~2~ dopamine receptors (K~i~ = 32nM). Evidence also indicates ITI-007 displays limbic dopamine system selectivity based on its ability to increase dopamine release in prefrontal cortex, but not striatum. Further, ITI-007 administration to animals does not increase striatal dopamine metabolism, indicating partial D~2~ receptors agonist activity at presynaptic striatal D~2~ receptors \[[@R23]\]. ITI-007 results in minimal motor side effects in animals as the ratio of the effective drug doses for the appearance of catalepsy, compared to blockade of hyperlocomotion, is \~30 \[[@R23]\], The absence of significant motor side effects seen in animals given ITI-007 likely owes to its unique combination of dopamine and serotonin receptor activities \[[@R23]\].

In summary, SGA medications and newer candidate therapeutics, like ITI-007, show an evolution from the pronounced motor side effect profile of FGA molecules, like haloperidol, to the most benign motor profile of ITI-007, without a significant loss of antipsychotic activity, as predicted from blockade of AMPH-induced locomotion (Table **4**). This evolution appears due, in part to design features introduced into new molecules, including serotonin receptor activities and dopamine receptor partial agonist properties.

3.3.. Comparison of Dopamine D~2~ Receptor Occupancy at Therapeutic Doses
-------------------------------------------------------------------------

Positron emission tomography (PET) imaging studies have demonstrated that clinical antipsychotic response is usually associated with at least 65% occupancy of striatal D~2~ dopamine receptors, while 50-73% occupancy can be associated with hyperprolactinemia and over 80% occupancy is associated with extrapyramidal side effects \[[@R173]-[@R180]\]. Therefore, it is difficult to achieve antipsychotic efficacy without concomitant motoric disturbances and hyperprolactinemia with both typical and atypical antipsychotic drugs. This relationship between D~2~ receptor occupancy, clinical response and side effects, even in first episode patients, is well-established \[[@R179]\].

Haloperidol, for example, often gives high (\>80%) striatal D~2~ receptor occupancy at therapeutic doses and results in motor disturbances such as parkinsonism and akathisia \[[@R174]\]. Similarly, risperidone, across its effective dose range of 4 to 12 mg/day, is associated with 72 -- 81% striatal D~2~ receptor occupancy \[[@R152], [@R175], [@R181]-[@R183]\]. With aripiprazole, D~2~ and D~3~ receptor occupancy levels are high, with average levels ranging between \~71% at a low, sub-therapeutic dose of 2 mg/day to \~96% at 40 mg/day \[[@R155], [@R184]\]. Although aripiprazole is associated with relatively less liability for parkinsonism, other motoric side effects such as akathisia occur at relatively high rates. Clozapine is an exception with relatively low striatal D~2~ receptor occupancy (\<60%) at antipsychotic doses and a low liability for parkinsonism, akathisia, and hyperprolactinemia \[[@R152], [@R174], [@R183], [@R185], [@R186]\]. At a low single dose of 10 mg in healthy volunteers, ITI-007 demonstrated low (\~12%) striatal D~2~ receptor occupancy and high (\>80%) cortical 5-HT~2A~ receptor occupancy \[[@R156]\]. ITI-007 demonstrated an average of 29% (peak of 39%) D~2~ occupancy at the highest evaluated dose in healthy volunteers. At a 40 mg dose, ITI-007 also demonstrated occupancy of serotonin transporters in healthy volunteers in a range similar to that of its D~2~ receptor occupancy, consistent with its *in vitro* pharmacological profile and antidepressant-like effects. In a double-blind, placebo-controlled efficacy trial, a dose of 60 mg ITI-007 was evaluated in patients with acute schizophrenia and demonstrated antipsychotic efficacy with a placebo-like motor side effect profile and no hyperprolactinemia \[[@R124]\]. Subsequently, 60 mg ITI-007 demonstrated approximately 40% striatal D~2~ receptor occupancy at plasma steady state after two weeks of administration in patients with schizophrenia who had been washed off their previous antipsychotic medications for at least two weeks prior to a within-subject baseline PET scan \[[@R125]\]. These data suggest that ITI-007 achieves antipsychotic efficacy at low levels of striatal D~2~ receptor occupancy yielding a lower risk for extrapyramidal side effects and hyperprolactinemia.

In summary, all clinically effective antipsychotics approved for the treatment of schizophrenia to date exhibit dopamine D~2~ receptor occupancy. High striatal D~2~ receptor occupancy was once thought to be required for antipsychotic efficacy, with clozapine as an exception. Growing evidence, including the recent example with ITI-007, suggests that sustained high levels of striatal D~2~ receptor occupancy are not required to achieve antipsychotic efficacy. A reduction in striatal D~2~ receptor occupancy also seems to provide safety and tolerability advantages, with reduced risk for motor side effects and hyperprolactinemia.

3.4.. Clinical Outcomes and Treatment-Emergent Side Effects
-----------------------------------------------------------

Clinical efficacy of marketed antipsychotic drugs, including haloperidol (**2**), clozapine (**3**), risperidone **(4**) and aripiprazole (**5**), has been extensively reviewed \[[@R187]-[@R192]\]. Examples from each generation of antipsychotics have demonstrated sufficient clinical efficacy compared to placebo in acute treatment trials to gain approval by regulatory authorities. The investigational drug candidate ITI-007 (**7**) also has demonstrated antipsychotic efficacy. ITI-007 (60 mg) exhibited efficacy with statistically significant superiority over placebo at Week 4 (study endpoint) as measured by the change from baseline on the PANSS total score (p=0.022) in a randomized, double-blind, placebo-controlled, multi-center phase III study for the treatment of patients with schizophrenia \[[@R125], [@R193]\]. ITI-007 showed a dose-related improvement in symptoms of schizophrenia with ITI-007 40 mg dose also demonstrating efficacy on several measures. Moreover, ITI-007 60 mg showed significant antipsychotic efficacy as early as week 1, which was maintained throughout the entire study. Patients treated with ITI-007 60 mg and 40 mg showed statistically significant improvement on the Clinical Global Impression Scale for Severity of Illness (CGI-S; p=0.003 for 60 mg, p=0.025 for 40 mg) \[[@R125]\]. Importantly, ITI-007 improved prosocial behavior and psychosocial function \[[@R124]\].

While only modest differences in efficacy have been observed among currently available antipsychotic drugs, their side effect profiles differ greatly \[[@R192]\]. Treatment decisions often are based on a weighing of risks and benefits of the various available antipsychotic drugs in light of individual history of treatment response and tolerability of particular side effects. The treatment-emergent side effects of the marketed antipsychotic drugs are different and mostly correlated with the receptor binding profiles of these compounds. Extrapyramidal syndrome is a commonly observed side effect, especially for the first generation antipsychotics, such as haloperidol, which generally require high striatal D~2~ receptor occupancy for efficacy and consequently result in motor disturbances such as parkinsonism and akathisia \[[@R174], [@R190]\]. It has been suggested for first-episode patients that aripiprazole may be considered as the preferred choice over risperidone; however, if the potential for akathisia and poor impulse control is a concern, low-dose risperidone may be a better choice over aripiprazole \[[@R191]\]. Clozapine demonstrated less severe motoric side effects, which is likely due to the relatively lower D~2~ receptor occupancy at therapeutic doses \[[@R194]\]. However, clozapine's safety risks limit its use to patients with treatment-resistant schizophrenia with close safety monitoring. Additionally, the currently available antipsychotic drugs exhibit various degrees of metabolic and endocrine abnormalities. Clozapine and risperidone are in particular associated with significant weight gain, especially in children and adolescents \[[@R195]\]. Aripiprazole exhibits relatively less metabolic side-effects than other commonly used atypical antipsychotic drugs \[[@R196]\], but at an increased risk for akathisia. In addition to motoric and metabolic adverse effects, various cardiovascular side effects are associated with the marketed antipsychotic drugs \[[@R197]-[@R199]\]. Clozapine is known to cause myocarditis and cardiomyopathy \[[@R200]\].

In clinical trials to date, ITI-007 (**7**) is well-tolerated and demonstrates a favorable safety profile that does not differ from placebo \[[@R124]\]. At therapeutic doses, ITI-007 did not show significant difference from placebo on weight gain, prolactin levels and metabolic parameters including cholesterol, triglycerides, glucose and insulin. ITI-007 was associated with low rates of motor side effects, including akathisia, similar to placebo. Key measures of cardiovascular function, including heart rate, QTc intervals and other ECG parameters, were also similar between ITI-007 and placebo \[[@R124]\]. These clinical observations suggest that ITI-007 is not associated with the usual side effects of existing medications for schizophrenia. An effective dose of 60 mg ITI-007 is associated with approximately 40% striatal D~2~ receptor occupancy, substantially lower than that required by other antipsychotic drugs \[[@R125], [@R156]\]. This sparing of D~2~ receptor occupancy likely contributes to ITI-007's reduced liability for motor side effects and hyperprolactinemia.

CONCLUSION
==========

Currently available antipsychotic treatments demonstrate efficacy for the treatment of positive symptoms associated with schizophrenia, but do not address the wide array of symptoms and psychosocial impairment experienced by people living with this disorder. Moreover, people living with schizophrenia and their treating psychiatrists often have to choose between varying side effect profiles, trading off cardiometabolic disturbances for motor dysfunction or vice versa. The vast majority (74%) of patients discontinue their study medication within 18 months \[[@R163]\]. Psychosocial functioning is at best modestly improved with currently available treatments, likely related to high early treatment discontinuation rates \[[@R201]\]. Better treatment options are clearly needed. Improving tolerability while maintaining efficacy would likely result in increased treatment adherence and improved psychosocial outcome. Dissociation of antipsychotic efficacy from high dopamine D~2~ receptor occupancy is one strategy for improving tolerability by reducing motoric liability. Limiting off-target pharmacological interactions associated with cardiometabolic burden will improve overall safety and tolerability profiles. Engagement across essential dopaminergic, serotonergic and glutamatergic targets may offer relief of a broad array of symptoms associated with schizophrenia, including a primary improvement in social function. Novel drug candidates designed to provide such improvements are currently in development for the treatment of schizophrenia.
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###### 

Receptor binding affinity of the first generation antipsychotics in the butyrophenones chemical class.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Receptor**\        **Haloperidol (2)**   **Bromperidol (18)**   **Trifluperidol (19)**   **Benperidol (21)**   **Droperidol (22)**   **Pipamperone (23)**   **Spiperone (24)**
  **Ki (nM) ^1^**                                                                                                                                               
  -------------------- --------------------- ---------------------- ------------------------ --------------------- --------------------- ---------------------- --------------------
  D~2~                 2.0                   2.1                    0.4                      0.027                 0.25                  120                    0.053

  D~1~                 83                    600                    740                      4100                  880                   4900                   577

  D~3~                 4.0                   2.3                    4.2                      NA                    NA                    250                    0.28

  D~4~                 15                    48                     326                      0.066                 0.84                  5.1                    1.4

  D~5~                 147                   NA^2^                  NA                       NA                    NA                    NA                     4500

  5-HT~1A~             1200                  NA                     NA                       NA                    NA                    2770                   209

  5-HT~2A~             70                    26                     5.4                      3.7                   4.6                   5.4                    1.41

  5-HT~2C~             5000                  NA                     NA                       NA                    NA                    227                    1108

  α~1~ adrenergic      12                    NA                     NA                       NA                    NA                    66                     25

  H~1~ histaminergic   3000                  NA                     NA                       NA                    NA                    2400                   476

  M~1~ muscarinic      \>10000               7600                   NA                       NA                    NA                    NA                     NA
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Receptor binding affinities were obtained from the NIMH Psychoactive Drug Screening Program (PDSP) Database \[[@R61]\].^2^ NA stands for not available.

###### 

Receptor Binding Affinity of Representative Second-Generation Antipsychotic Drugs.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Receptor**\        **Clozapine**\   **Olanzapine (32)**   **Quetiapine (33)**   **Risperidone (4)**   **Paliperidone (34)**   **Sertindole (36)**   **Lurasidone ^3^ (38)**
  **Ki (nM)^1^**       **(3)**                                                                                                                          
  -------------------- ---------------- --------------------- --------------------- --------------------- ----------------------- --------------------- -------------------------
  D~2~                 144              21                    245                   4.9                   2.8                     2.7                   1.0

  D~1~                 189              58                    1277                  147                   41                      12                    262

  D~3~                 270              49                    240                   3.6                   6.9                     2.5                   15.7

  D~4~                 39               14                    2000                  4.4                   54                      9.0                   29.7

  D~5~                 235              90                    1738                  563                   29                      NA ^2^                NA

  5-HT~1A~             105              2063                  431                   427                   638                     280                   6.4

  5-HT~2A~             5.2              2.65                  135                   0.17                  1.2                     0.28                  0.47

  5-HT~2C~             10.7             14                    1184                  12                    48                      0.90                  415

  α~1A~ adrenergic     1.6              109                   22                    5.0                   2.5                     1.8                   NA

  α~1B~ adrenergic     7.0              263                   39                    9.0                   0.70                    NA                    NA

  H~1~ histaminergic   2.0              4.9                   7.5                   15                    5.6                     130                   \>1000

  M~1~ muscarinic      14               24                    120                   \>10,000              \>10,000                NA                    \>1000
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Receptor binding affinities were obtained from the NIMH Psychoactive Drug Screening Program (PDSP) Database \[[@R61]\].^2^NA stands for not available. ^3^ Data from the cited literatures \[[@R27], [@R102], [@R103]\].

###### 

Receptor binding profiles of aripiprazole (**5**) and other dopamine partial agonists as atypical antipsychotics.

  **Receptor Ki (nM) ^1^**   **Aripiprazole (5) ^3^**   **Brexpiprazole (6) ^4^**   **Cariprazine (40) ^5^**
  -------------------------- -------------------------- --------------------------- --------------------------
  D~2~                       0.34                       0.30                        0.49
  D~1~                       1960                       160                         NA
  D~3~                       0.8                        1.1                         0.085
  D~4~                       44                         6.3                         NA ^2^
  D~5~                       2590                       NA                          NA
  5-HT~1A~                   1.7                        0.12                        2.6
  5-HT~2A~                   3.4                        0.47                        18.6
  5-HT~2C~                   15                         34                          135
  α~1A~ adrenergic           26                         3.8                         132
  α~1B~ adrenergic           35                         0.17                        \>1000
  H~1~ histaminergic         61                         19                          23.4
  M~1~ muscarinic            6780                       67% inhibition at 10 μM     NA

^1^Receptor binding affinities were obtained from the NIMH Psychoactive Drug Screening Program (PDSP) Database \[[@R61]\].^2^NA stands for not available. ^3^ Data from the cited literatures \[[@R108], [@R120]\]. ^4^ Data from the cited literatures \[[@R121], [@R122]\]. ^5^ Data calculated based upon the pKi reported in the cited literature \[[@R118]\].

###### 

Comparison of biochemical and pharmacological properties of representative antipsychotics, haloperidol, clozapine, risperidone, aripiprazole and ITI-007.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                   **Haloperidol (2)**                                                                      **Clozapine (3)**                                                                                                                                   **Risperidone (4)**                                                                                                      **Aripiprazole (5)**                                                                                                                                                                                                       **ITI-007 (7)**
  ------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Receptor binding (Ki, nM)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  D~2~                                                                                             2.0                                                                                      144                                                                                                                                                 4.9                                                                                                                      0.34                                                                                                                                                                                                                       32

  D~1~                                                                                             83                                                                                       189                                                                                                                                                 147                                                                                                                      1960                                                                                                                                                                                                                       52

  D~3~                                                                                             4.0                                                                                      270                                                                                                                                                 3.6                                                                                                                      0.8                                                                                                                                                                                                                        \> 100

  D~4~                                                                                             15                                                                                       39                                                                                                                                                  4.4                                                                                                                      44                                                                                                                                                                                                                         108

  D~5~                                                                                             147                                                                                      235                                                                                                                                                 563                                                                                                                      2590                                                                                                                                                                                                                       \> 100

  5-HT~1A~                                                                                         1202                                                                                     105                                                                                                                                                 427                                                                                                                      1.7                                                                                                                                                                                                                        1480

  5-HT~2A~                                                                                         70                                                                                       5.2                                                                                                                                                 0.17                                                                                                                     3.4                                                                                                                                                                                                                        0.54

  5-HT~2C~                                                                                         5000                                                                                     10.7                                                                                                                                                12                                                                                                                       15                                                                                                                                                                                                                         173

  α~1A~ adrenergic                                                                                 12                                                                                       1.6                                                                                                                                                 5.0                                                                                                                      26                                                                                                                                                                                                                         73

  α~1B~ adrenergic                                                                                 8                                                                                        7.0                                                                                                                                                 9.0                                                                                                                      35                                                                                                                                                                                                                         31

  H~1~ histamine                                                                                   3002                                                                                     2.0                                                                                                                                                 15                                                                                                                       61                                                                                                                                                                                                                         \> 1000

  M~1~ muscarinic                                                                                  \>10000                                                                                  14                                                                                                                                                  \>10,000                                                                                                                 6780                                                                                                                                                                                                                       \> 1000

  SERT                                                                                             3256                                                                                     1624                                                                                                                                                \> 10,000                                                                                                                1080 \[[@R120]\]                                                                                                                                                                                                           61

  NET                                                                                              2112                                                                                     3168                                                                                                                                                5454                                                                                                                     2093                                                                                                                                                                                                                       \> 1000

  DAT                                                                                              \> 10,000                                                                                \> 10,000                                                                                                                                           \> 10,000                                                                                                                3215                                                                                                                                                                                                                       \> 1000

  **Ratio of Ki values**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  D~2~/5-HT~2A~                                                                                    0.029                                                                                    28                                                                                                                                                  29                                                                                                                       0.10                                                                                                                                                                                                                       59

  5-HT~2C~/5-HT~2A~                                                                                71                                                                                       2.1                                                                                                                                                 71                                                                                                                       4.4                                                                                                                                                                                                                        320

  H~1~/5-HT~2A~                                                                                    43                                                                                       0.38                                                                                                                                                88                                                                                                                       18                                                                                                                                                                                                                         \> 1850

  Mechanism of action (receptor functionality)                                                     D~2~ and D~3~ inverse agonist \[[@R142]\]                                                Antagonist at dopaminergic, adrenergic, cholinergic, histaminergic and\                                                                             Antagonist at serotonin 5-HT~2~, dopamine D~2~, adrenergic α~1~ and α~2~, and histaminergic H~1~ receptors \[[@R144]\]   D~2~ and 5-HT~1A~ partial agonist;\                                                                                                                                                                                        5-HT~2A~ antagonist; post synaptic antagonist and pre-synaptic partial agonist at dopamine D~2~ receptors; glutamatergic phosphoprotein modulator; serotonin reuptake inhibitor \[[@R23]\]
                                                                                                                                                                                            serotonergic receptors \[[@R143]\]                                                                                                                                                                                                                                           5-HT~2A~ antagonist \[[@R108]\]                                                                                                                                                                                            

  Blockade of Amphetamine-induced hyperlocomotion ED~50~ (mg/kg, PO)                               0.04 \[[@R23]\]                                                                          4.27 \[[@R145]\]                                                                                                                                    0.33 \[[@R23]\]                                                                                                          4.65 \[[@R23]\]                                                                                                                                                                                                            0.95 \[[@R23]\]

  Ratio of effective dose for catalepsy induction/effective dose for blockade of hyperlocomotion   1 \[[@R146], [@R147]\]                                                                   10 \[[@R146]\]                                                                                                                                      5 \[[@R146]\]                                                                                                            12 \[[@R146], [@R148]\]                                                                                                                                                                                                    \>30 \[[@R23]\]

  Target dosage for the treatment of adult schizophrenia                                           2- 5 mg every 4- 8 hours \[[@R149]\]                                                     300 -- 450 mg/day; 900 mg/day maximum                                                                                                               4 -- 8 mg/day; 16 mg/day maximum                                                                                         10 -- 15 mg/day recommended dose; 30 mg/day maximum                                                                                                                                                                        40 -- 60 mg/day\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \[[@R124], [@R125]\]

                                                                                                   **Haloperidol (2)**                                                                      **Clozapine (3)**                                                                                                                                   **Risperidone (4)**                                                                                                      **Aripiprazole (5)**                                                                                                                                                                                                       **ITI-007 (7)**

  Dose frequency                                                                                   Every 4- 8 hours                                                                         Three times a day                                                                                                                                   once or twice daily                                                                                                      Once daily                                                                                                                                                                                                                 Once daily

  Dose titration requirement                                                                       Required                                                                                 Required to achieve efficacious dose                                                                                                                Required to achieve efficacious dose                                                                                     Required to achieve maximum dose                                                                                                                                                                                           None

  Dopamine D~2~ receptor occupancy at therapeutic doses                                            53 -- 74% at 2 mg/day \[[@R150]\];\                                                      24.5% at 250 mg/day; \< 60% at 400 -- 600 mg/day \[[@R152], [@R174]\]                                                                               73% at 4 mg/day \[[@R153], [@R182]\]                                                                                     83.5 ± 3.2% at 15 mg/day; 96.8 ± 5.3% at 40 mg/day \[[@R154], [@R155]\]                                                                                                                                                    \~ 40% at 60 mg/day \[[@R125], [@R156]\]
                                                                                                   53 -- 88% at 1 -- 5 mg/day \[[@R151]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Approved indications                                                                             Schizophrenia; control of tics and vocal utterances of Tourette's Disorder \[[@R149]\]   Treatment-Resistant Schizophrenia; reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorders \[[@R143]\]   Schizophrenia; acute manic or mixed episodes associated with bipolar I\                                                  Schizophrenia; acute treatment of manic and mixed episodes associated with bipolar I disorder; adjunctive treatment of MDD; irritability associated with autistic Disorder; treatment of Tourette's disorder \[[@R108]\]   Investigational new drug currently in phase III clinical development
                                                                                                                                                                                                                                                                                                                                                disorder; treatment of irritability associated with autistic disorder \[[@R144]\]                                                                                                                                                                                                                                                                   

  Other indications in phase III clinical trials                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Schizophrenia; bipolar depression
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
